申请人:Takeda Pharmaceutical Company Limited
公开号:EP1705176A1
公开(公告)日:2006-09-27
The present invention relates to a compound represented by the formula
wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B and ring C are each an aromatic ring optionally having substituent(s), R1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group or a heterocyclic group optionally having substituent(s), Z is an optionally halogenated C1-6 alkyl group, Y is a methylene group optionally having substituent(s), m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof. The compound of the present invention has a superior tachykinin receptor antagonistic action, particularly an SP receptor antagonistic action, and is useful as a pharmaceutical agent, for example, a tachykinin receptor antagonist, an agent for the prophylaxis or treatment of an abnormality of lower urinary tract functions, a digestive organ disease or a central nerve disease, and the like.
本发明涉及一种由式表示的化合物
其中环 A 是可选进一步具有取代基的含氮杂环,环 B 和环 C 各是可选具有取代基的芳香环,R1 是氢原子、可选具有取代基的烃基、酰基或可选具有取代基的杂环基团,Z 是可选被卤化的 C1-6 烷基,R2 是可选被卤化的 C1-6 烷基,R3 是可选被卤化的 C1-6 烷基,R4 是可选被卤化的 C1-6 烷基、Z 是可选的卤代 C1-6 烷基,Y 是可选的亚甲基,m 和 n 分别是 0 至 5 的整数,m+n 是 2 至 5 的整数,并且是单键或双键,或其盐。本发明的化合物具有优异的速激肽受体拮抗作用,特别是 SP 受体拮抗作用,可用作药物制剂,例如速激肽受体拮抗剂,预防或治疗下尿路功能异常、消化器官疾病或中枢神经疾病等的药物。